Published in:
Open Access
01-12-2015 | Review
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Authors:
Shundong Cang, Chaitanya Iragavarapu, John Savooji, Yongping Song, Delong Liu
Published in:
Journal of Hematology & Oncology
|
Issue 1/2015
Login to get access
Abstract
With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.